In gouty arthritis induced by monosodium urate crystal, the in vivo therapeutic effects of dioscin may be accomplished by inhibiting the increase in stromal cell-derived factor-1 (SDF-1), CXCR4 (receptor of SDF-1) and p38 MAPK signaling in synovial tissue of rats [154]. This evidence concerns the gene CXCL12 and gout.